Stock Under $10 with 50-100% upside potential - 14 Days FREE!

6 Stocks Rising on Huge Volume

Stock quotes in this article: DNDN, QCOR, NFLX, TRNX, LCRY, VVUS 

Questor Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Questor Pharmaceuticals (QCOR), a biopharmaceutical company, provides prescription drugs for the treatment of auto-immune diseases. The stock is trading up 8% at $42.11 in recent trading.

Today's Volume: 2.4 million

Average Volume: 1.1 million

Volume % Change: 241%

Shares of QCOR are ripping higher today after the company announced sales of its H.P. Acthar Gel that exceeded analyst expectations. The company shipped 3,360 vial of the gel vs. 1,680 shipped in the fourth quarter of 2010.

From a technical standpoint, QCOR is starting to gap up big today back above its 50-day moving average of $42.25 on heavy volume. Traders should now watch for a sustained move and close above $42.25 to signal that this stock wants to re-test some major overhead resistance at close to $46.

I would consider it a major breakout if QCOR can take out $46 with volume in the coming days or weeks.

Questcor shows up on recent lists of 3 Low-PEG, High-Momentum Stocks and 5 Drug Stock Winners of 2011.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,401.63 14.05 0.09%
NASDAQ 3,502.12 5.69 0.16%
S&P 500 1,669.16 2.87 0.17%
US 10 Yr 1.923% -0.021

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs